1. Home
  2. LGIH vs DBVT Comparison

LGIH vs DBVT Comparison

Compare LGIH & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LGI Homes Inc.

LGIH

LGI Homes Inc.

HOLD

Current Price

$64.06

Market Cap

1.2B

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$16.04

Market Cap

948.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGIH
DBVT
Founded
2003
2002
Country
United States
France
Employees
N/A
90
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
948.8M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
LGIH
DBVT
Price
$64.06
$16.04
Analyst Decision
Hold
Buy
Analyst Count
5
7
Target Price
$75.90
$32.04
AVG Volume (30 Days)
379.1K
311.8K
Earning Date
04-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.26
EPS
0.09
N/A
Revenue
$1,705,504,000.00
$5,636,000.00
Revenue This Year
$2.32
$35.04
Revenue Next Year
$17.94
$2,360.78
P/E Ratio
$682.67
N/A
Revenue Growth
N/A
35.77
52 Week Low
$33.55
$8.51
52 Week High
$69.42
$26.19

Technical Indicators

Market Signals
Indicator
LGIH
DBVT
Relative Strength Index (RSI) 73.43 40.76
Support Level $41.87 $16.05
Resistance Level N/A $17.42
Average True Range (ATR) 3.06 0.98
MACD 0.86 -0.01
Stochastic Oscillator 96.92 23.49

Price Performance

Historical Comparison
LGIH
DBVT

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: